Institutes
Refine
Year of publication
Document Type
- Doctoral Thesis (311)
- Article (282)
- Preprint (38)
- Contribution to a Periodical (25)
- Book (18)
- Report (2)
Language
- English (521)
- German (154)
- Multiple languages (1)
Has Fulltext
- yes (676)
Is part of the Bibliography
- no (676)
Keywords
- RNA (12)
- SARS-CoV-2 (10)
- NMR spectroscopy (9)
- inflammation (9)
- photochemistry (9)
- NMR (8)
- Biochemistry (7)
- Cell biology (7)
- E2 enzyme (6)
- TRACT (6)
Institute
- Biochemie, Chemie und Pharmazie (676)
- Präsidium (43)
- Medizin (35)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (31)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (30)
- Biowissenschaften (23)
- MPI für Biophysik (15)
- Physik (12)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (5)
- Geowissenschaften / Geographie (4)
A plethora of modified nucleotides extends the chemical and conformational space for natural occurring RNAs. tRNAs constitute the class of RNAs with the highest modification rate. The extensive modification modulates their overall stability, the fidelity and efficiency of translation. However, the impact of nucleotide modifications on the local structural dynamics is not well characterized. Here we show that the incorporation of the modified nucleotides in tRNAfMet from Escherichia coli leads to an increase in the local conformational dynamics, ultimately resulting in the stabilization of the overall tertiary structure. Through analysis of the local dynamics by NMR spectroscopic methods we find that, although the overall thermal stability of the tRNA is higher for the modified molecule, the conformational fluctuations on the local level are increased in comparison to an unmodified tRNA. In consequence, the melting of individual base pairs in the unmodified tRNA is determined by high entropic penalties compared to the modified. Further, we find that the modifications lead to a stabilization of long-range interactions harmonizing the stability of the tRNA’s secondary and tertiary structure. Our results demonstrate that the increase in chemical space through introduction of modifications enables the population of otherwise inaccessible conformational substates.
2-Aminobenzimidazole 10, although a weak catalyst in the monomeric state, is a successful building block for effective artificial ribonucleases. In an effort to identify new building blocks with improved catalytic potential, RNA cleavage by a variety of heterocyclic amidines and guanidines has been studied. In addition to pKa values and steric effects, the energy difference between tautomeric forms seems to be another important parameter for catalysis. This information is available from quantum chemical calculations on higher levels, but semiempirical methods are sufficient to get a first estimate. According to this assumption, imidazoimidazol 18, characterized by isoenergetic tautomeric forms, is superior to 2-aminoimidazol 6, the best candidate among the simple compounds. By far the largest effects are seen with 2-aminoperimidine 24, which rapidly cleaves RNA even in the micromolar concentration range. The impressive reactivity, however, is related to a tendency of compound 24 to form polycationic aggregates which are the actual catalysts.
2-Aminobenzimidazole 10, although a weak catalyst in the monomeric state, is a successful building block for effective artificial ribonucleases. In an effort to identify new building blocks with improved catalytic potential, RNA cleavage by a variety of heterocyclic amidines and guanidines has been studied. In addition to pKa values and steric effects, the energy difference between tautomeric forms seems to be another important parameter for catalysis. This information is available from quantum chemical calculations on higher levels, but semiempirical methods are sufficient to get a first estimate. According to this assumption, imidazoimidazol 18, characterized by isoenergetic tautomeric forms, is superior to 2-aminoimidazol 6, the best candidate among the simple compounds. By far the largest effects are seen with 2-aminoperimidine 24, which rapidly cleaves RNA even in the micromolar concentration range. The impressive reactivity, however, is related to a tendency of compound 24 to form polycationic aggregates which are the actual catalysts.
Diversity-oriented synthesis (DOS) is a rich source for novel lead structures in Medicinal Chemistry. In this study, we present a DOS-compatible method for synthesis of compounds bearing a free thiol moiety. The procedure relies on Rh(II)-catalyzed coupling of dithiols to diazo building blocks. The synthetized library was probed against metallo-β-lactamases (MBLs) NDM-1 and VIM-1. Biochemical and biological evaluation led to identification of novel potent MBL inhibitors with antibiotic adjuvant activity.
Photoactivatable compounds for example photoswitches or photolabile protecting groups (PPGs, photocages) for spatiotemporal light control, play a crucial role in different areas of research. For each application, parameters such as the absorption spectrum, solubility in the respective media and/or photochemical quantum yields for several competing processes need to be optimized. The design of new photochemical tools therefore remains an important task. In this study, we exploited the concept of excited-state-aromaticity, first described by N. Colin Baird in 1971, to investigate a new class of photocages, based on cyclic, ground-state-antiaromatic systems. Several thio- and nitrogen-functionalized compounds were synthesized, photochemically characterized and further optimized, supported by quantum chemical calculations. After choosing the optimal scaffold, which shows an excellent uncaging quantum yield of 28 %, we achieved a bathochromic shift of over 100 nm, resulting in a robust, well accessible, visible light absorbing, compact new photocage with a clean photoreaction and a high quantum product (ϵ⋅Φ) of 893 M−1 cm−1 at 405 nm.
Photoactivatable compounds for example photoswitches or photolabile protecting groups (PPGs, photocages) for spatiotemporal light control, play a crucial role in different areas of research. For each application, parameters such as the absorption spectrum, solubility in the respective media and/or photochemical quantum yields for several competing processes need to be optimized. The design of new photochemical tools therefore remains an important task. In this study, we exploited the concept of excited-state-aromaticity, first described by N. Colin Baird in 1971, to investigate a new class of photocages, based on cyclic, ground-state-antiaromatic systems. Several thio- and nitrogen-functionalized compounds were synthesized, photochemically characterized and further optimized, supported by quantum chemical calculations. After choosing the optimal scaffold, which shows an excellent uncaging quantum yield of 28 %, we achieved a bathochromic shift of over 100 nm, resulting in a robust, well accessible, visible light absorbing, compact new photocage with a clean photoreaction and a high quantum product (ϵ⋅Φ) of 893 M−1 cm−1 at 405 nm.
Das Glykoprotein AICL gehört zur Familie der C-Typ Lektin-ähnlichen Rezeptoren und wird nach Aktivierung humaner NK Zellen und Makrophagen auf deren Oberfläche exprimiert. Die Bindung von AICL an den genetisch gekoppelten, aktivierenden NKRezeptor NKp80, der auf allen reifen humanen NK Zellen exprimiert ist, induziert Effektorfunktionen von NK Zellen, wie Zytotoxizität und Zytokinsekretion. AICL Glykoproteine werden in ruhenden NK Zellen intrazellulär zurückgehalten und gelangen erst nach Zellaktivierung an die Oberfläche (Klimosch et al. 2013). Der Mechanismus dieser Regulation ist bisher unbekannt und sollte im Rahmen dieser Arbeit untersucht werden, um weitere Einblicke in die Funktion des NKp80-AICL Rezeptor-Ligand-Paares im Rahmen einer Immunantwort zu ermöglichen.
In dieser Arbeit konnte gezeigt werden, dass nach der Aktivierung von NK Zellen sowohl präformierte im Golgi-Komplex zurückgehaltene als auch de novo synthetisierte AICL Glykoproteine an die Zelloberfläche gelangen. Bei der intrazellulären Retention von AICL handelt es sich um eine intrinsische Eigenschaft von AICL, die auch im ektopen Kontext von Insektenzellen auftritt. Mechanistisch konnte gezeigt werden, dass die N-Glykosylierungen von AICL differentiell die AICLOberflächenexpression bestimmen. Die AICL Ektodomäne wird an einer nichtkonventionellen (N-X-C) und an drei konventionellen (N-X-S/T) N-Glykosylierungsstellen glykosyliert, wobei die Glykosylierung an ersterer ineffizient ist, sodass stets zwei Glykoisoformen vorhanden sind. Während die Glykosylierung zumindest einer konventionellen Stelle essenziell für die AICL-Oberflächenexpression ist, und diese mit zunehmender Glykosylierung konventioneller Stellen zunimmt, vermindert die nichtkonventionelle Glykosylierungsstelle die AICL-Oberflächenexpression. Für eine effiziente Oberflächenexpression ist auch die Ausbildung einer nicht-konservierten Disulfidbrücke erforderlich, die im membran-distalen Bereich der C-Typ Lektindomäne AICL-Homodimere miteinander verknüpft. Das Fehlen dieser Disulfidbrücke führt auch zu dem Verlust der NKp80-Bindung. Die intrazelluläre Reifung von AICL Glykoproteinen ist, im Gegensatz zu dem verwandten Glykoprotein KACL, in besonderem Maße abhängig von der Interaktion mit den ER-ständigen Proteinen der Proteinqualitätskontrolle. Insbesondere konnte mit Hilfe massenspektrometrischer Analysen eine starke Interaktion von AICL mit dem ER Chaperone Calnexin gezeigt werden. Entsprechend ist die zelluläre Expression von AICL in Abwesenheit von Calnexin stark reduziert. Massenspektrometrisch konnte auch eine spezifische Interaktion von AICL mit dem Protein ITM2A gezeigt werden, wobei allerdings eine funktionelle Relevanz in Folgeversuchen nicht bestätigt werden konnte. Schließlich konnte eine zusätzliche Regulation der AICL-Oberflächenexpression durch proteasomale Degradation nachgewiesen werden, die über zwei Lysine im kurzen zytoplasmatischen Bereich von AICL bestimmt wird.
Frühere Untersuchungen hatten eine Bindung von sowohl AICL- als auch NKp80-Ektodomänen an K562 Zellen, eine Erythroleukämie-zelllinie, ergeben. Da K562 Zellen weder NKp80 noch AICL exprimieren, handelt es sich bei der gebundenen Struktur um einen potenziellen weiteren Liganden des NKp80-AICL Rezeptor-Ligand-Paares. Hier konnte gezeigt werden, dass es sich bei der Bindestruktur um ein Oberflächenprotein der K562 Zellen handelt, das allerdings nicht identifiziert werden konnte.
Insgesamt konnten im Rahmen dieser Arbeit mehrere AICL-spezifische, molekulare Mechanismen identifiziert und charakterisiert werden, die die aktivierungsabhängige Oberflächenexpression von AICL regulieren. Offensichtlich unterliegt diese einer strikten Kontrolle auf mehreren Ebenen, was vermutlich mit der Funktion von AICL als Ligand für einen aktivierenden Immunrezeptor auf zytotoxischen NK Zellen erklärbar ist. Weitere Untersuchungen zur AICL-Expressionsregulation und zur Funktion des NKp80-AICL Rezeptor-Ligand-Paares in vivo sind erforderlich, um ein besseres Verständnis der Immunbiologie von NK Zellen zu erreichen.
The innate immune system is the first line of host defense that senses invading pathogens by various surveillance mechanisms, involving pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs). Furthermore, in response to stress, tissue injury or ischemia, cells release endogenous danger-associated molecular patterns (DAMPs) which activate PRRs in order to prompt an effective immune response. Activation of PRRs by DAMPs initiates signaling transduction pathways which drive sterile inflammation by the production of pro-inflammatory effector molecules. Biglycan, a class I small leucine-rich proteoglycan (SLRP), is proteolytically released from the extracellular matrix (ECM) in response to tissue stress and injury or de novo synthesized by activated macrophages. In its soluble form, biglycan operates as an ECM-derived DAMP and triggers a potent inflammatory response by engaging TLR2 and TLR4 on immune cells. By selective utilization of TLR2/4 and the TLR adaptor molecules adaptor molecule myeloid differentiation primary response gene 88 (MyD88) or TIR domain-containing adaptor-inducing interferon-β (TRIF) biglycan differentially regulates the production of TLR downstream mediators or inflammatory molecules. In this way, biglycan triggers the activation of mitogen-activated protein kinase (MAPK) p38, extracellular signal-regulated kinase (Erk) and nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) in a primarily MyD88-dependent manner. In contrast, biglycan induces the expression of (C–C motif) ligand (CCL)5 and chemokine (C-X-C motif) ligand (CXCL)10 over TLR4/TRIF, heat shock protein 70 (HSP70) production over TLR2 and the synthesis of tumor necrosis factor (TNF)-α, CCL2 and CCL20 by utilizing TLR2/4/MyD88. As a consequence, biglycan promotes the recruitment of immune cells such as neutrophils, T cells, B cells and macrophages into the inflamed tissue. Research over the past years showed that biglycan-induced inflammation is involved in the pathogenesis of various inflammatory diseases such as lupus nephritis (LN), sepsis and renal ischemia/reperfusion injury (IRI), whereby genetic deletion of biglycan or TLR2/4 alleviated disease outcome. Unfortunately, the selective interaction of biglycan to TLRs and TLR adaptors complicates the identification of an efficient pharmacological target in biglycan-mediated inflammation. Yet, the necessity of possible co-receptors in biglycan signaling such as cluster of differentiation 14 (CD14) which was found in a high molecular complex with biglycan was not addressed so far.
In the first part of the present study, by utilizing primary peritoneal murine macrophages we demonstrated that the biglycan-induced expression and synthesis of TNF-α and CCL2 via TLR2/4/MyD88, CCL5 through TLR4/TRIF and HSP70 over TLR2 is blunted in CD14 deficient mice, proving that CD14 is essential in TLR2- and TLR4-mediated biglycan signaling. Pre-incubation of macrophages with an anti-CD14 antibody significantly reduced the protein levels of TNF-α, CCL2, CCL5 and HSP70. In line with these data, pharmacological inhibition of CD14 alleviated the transcriptional activation of NF-κB by biglycan in HEK-Blue cells expressing hTLR2/CD14 as well as hTLR4/CD14/MD2 supporting CD14-dependency for biglycan/TLR2/4 signaling. Western blot analysis of phosphorylated p38, p44/42 and NF-κB in WT and CD14 deficient mice revealed that activation of biglycan-mediated TLR downstream signaling is CD14-dependent. Accordingly, biglycan-induced activation and nuclear translocation of p38, p44/42 and NF-κB was blocked in Cd14-/- mice as analyzed by confocal microscopy. Co-immunoprecipitation studies combined with microscale thermophoresis analysis showed that biglycan is in complex with CD14 in macrophages and in vitro binds directly with high affinity to CD14, thereby sustaining the concept that CD14 is a novel co-receptor in biglycan-mediated inflammation. Additionally, we provided proof-of-principle of our concept in an in vivo mouse model of renal IRI. Transient overexpression of biglycan in WT mice exacerbated the expression and production of TNF-α, CCL2, CCL5 and HSP70 in a CD14-dependent manner. Interestingly, pLIVE or pLIVE-hBGN-injected Cd14-/- mice displayed lower chemo- and cytokine levels in reperfused kidneys as compared to respective WT controls during renal IRI (30 h), indicating a renoprotective effect by CD14 deficiency. Flow cytometry analysis of kidney homogenates underlined the pivotal effect of CD14 in biglycan signaling as biglycan-mediated infiltration of CD11b- and F4/80-positive renal macrophages was abolished in Cd14-/- mice. Additionally, pLIVE or pLIVE-hBGN-injected CD14 deficient mice displayed lower numbers of renal CD11b- and F4/80-positive cells during renal IRI compared to WT mice. Analysis of F4/80- and CD38-positive cells isolated from mononuclear cell extracts from kidney homogenates of pLIVE or pLIVE-hBGN-injected WT and Cd14-/- mice revealed that biglycan triggers the polarization of pro-inflammatory M1 macrophages in a CD14-dependent manner. In line with this, Cd14-/- mice, either injected with pLIVE or pLIVE-hBGN, showed less F4/80- and CD38-positive cells during renal IRI than the respective WT control. As a corroboration of our data PAS-stained renal sections of pLIVE- or pLIVE-hBGN-injected WT or Cd14-/- mice uncovered that biglycan worsens tubular damage in IRI-subjected mice via CD14. At the same time, tubular damage was significantly reduced in IRI-subjected Cd14-/- mice as compared to WT mice. In correlation with these data, serum creatine levels were increased in pLIVE-hBGN-injected WT mice during renal IRI. In contrast, serum creatine levels were significantly less increased in pLIVE- or pLIVE-hBGN-injected Cd14-/- mice than in WT littermate controls. In conclusion we demonstrated that CD14 is a new high affinity ligand for biglycan-mediated pro-inflammatory signaling over TLR2 and TLR4 in macrophages. In vivo, soluble biglycan triggers the expression of various inflammatory mediators by utilizing the co-receptor CD14. Ablation of CD14 abolishes biglycan-induced renal macrophage infiltration and M1 macrophage polarization as well as overall kidney function by reduced tubular damage and serum creatinine levels. Therefore, this study identifies CD14 as a promising therapeutic target to ameliorate biglycan-induced inflammation.
...
The human Long Interspersed Nuclear Element-1 (LINE-1, L1) is a member of the group of autonomous non-LTR retrotransposons found in almost every eukaryotic genome. L1 elements generate copies of themselves by reverse transcription of an RNA intermediate and integrate into the host genome by a process called Target Primed Reverse Transcription (TPRT). They are responsible for the generation of approximately 35% of the human genome, cover about 17% of the genome and represent the only group of active autonomous transposable elements in humans. L1 activity bears several risks for the integrity of the human genome, since the L1-encoded protein machinery generates DNA double-strand breaks (DSBs) and is capable of conducting numerous genome-destabilizing effects, e.g. causing deletions at insertion sites, disrupting or rearranging coding sequences and deregulating transcription of functional host genes. On the other side, L1 elements have had and still exert a great impact on human genome structure and evolution by increasing the genome size and rearranging and modulating gene expression. Furthermore, due to its endogenous and generally non-pathogenic nature, L1 is a promising candidate as vector for gene delivery in somatic gene therapy. The structure of the flanking regions between de novo L1 integrants and the genomic sequence suggests an involvement of cellular DSB repair pathways in L1 mobilization. To elucidate the role of DSB repair proteins in L1 retrotransposition, I disabled DSB repair factors ATM, ATR, DNA-PK, p53 and Ku70 by knock down (KD) using short hairpin RNA (shRNA) expression constructs. To inhibit the function of DSB repair factors PARP and Rad51, I used dominant negative (DN) PARP and Rad51 mutants. Applying a well established L1-retrotransposition reporter assay in HeLa cells, de novo retrotransposition events were launched in order to test L1 for its retrotransposition activity in the context of altered DSB repair conditions. I could show that L1 retrotransposition frequency after ATM KD had increased by 3-fold, while ATR and p53 KD reduced L1 retrotransposition by approximately one third. Unfortunately, the cytotoxic effects of the DNA-PK and Ku70 shRNA expression constructs were too strong to determine potential effects of DNA-PK and Ku70 KD on L1 retrotransposition. Inhibition of PARP function by expression of the DN mutant and overexpression of wild type PARP were found to increase L1 retrotransposition by 1.8 and 1.5, respectively, while Rad51 DN had no detectable effect. Interestingly, overexpression of wild type Rad51 seemed to roughly double L1 retrotransposition frequencies. Since in my experiments KD or expression of DN mutants was time-delayed to the onset of L1 retrotransposition after transfection into the cells, I developed a temporally controllable, tetracyclin transactivator (tTA)-dependent L1 retrotransposition reporter assay which will be of great value for future L1 retrotransposition studies that rely on temporally controllable retrotransposition. Due to a previously published hypothesis of L1 playing a role in brain development by contributing to somatic mosaicism in neuronal precursor cells, I generated a transgenic mouse (LORFUS) using the tTA-dependent L1 construct to further test this hypothesis. LORFUS harbors a bidirectional cassette driving simultaneous expression of a GFP-tagged L1 retrotransposition reporter and beta-galactosidase. It was bred to another transgenic mouse line expressing tTA in the forebrain. The double transgenic offspring was used to characterize L1 expression and retrotransposition patterns in the brain at postnatal day 15 (P15). General transgene expression indicated by beta-galactosidase activity was found in hippocampus, cortex and striatum, while retrotransposition events revealed by GFP expression were found in hippocampus, cortex, striatum, olfactory bulb and brainstem. These results suggested L1 retrotransposition in the granule layer of the dentate gyrus earlier than P15 and migration of cells carrying these events along the rostral migratory stream into the olfactory bulb. To facilitate the use of L1 as gene delivery tool in gene therapy or genetic engineering, I furthermore intended to manipulate the L1 target site recognition to allow the site-specific integration into defined genomic locations. To this end, I performed crystal structure-guided mutational analysis exchanging single amino acid residues within the endonuclease (EN) domain of L1 to identify residues influencing target site recognition. However, individual point mutations did not change the nicking pattern of L1-EN, but resulted in a reduction of endonucleolytic activity reflected by a reduced retrotransposition frequency. This suggests that additional factors other than the DNA nicking specificity of L1-EN contribute to the targeted integration of non-LTR retrotransposons in the host genomes.
Acute lymphoblastic leukemia (ALL), a neoplastic disorder of blood cells of the lymphoid lineage, is the most frequent childhood cancer. In spite of increasing survival rates, the outcome for adults, infants or relapsed patients is still less favorable, highlighting the need for novel treatment options. Reactive oxygen species (ROS) are important signaling molecules that are involved in a variety of cellular pathways. As high ROS levels lead to oxidative stress and irreversible oxidation of cellular macromolecules, the production and elimination of ROS is tightly controlled. Therefore, cells express several antioxidant molecules and enzymes, including glutathione, catalase and the thioredoxin (Trx) system, to balance ROS levels. As cancer cells were found to have increased ROS levels that could contribute to tumor progression and metastasis, they rely strongly on these antioxidant systems to prevent oxidative damage, making cancer cells especially vulnerable to ROS-inducing treatments. ROS and oxidative stress have been shown to induce programmed cell death via different pathways, however the exact mechanisms that couples oxidative signaling and cell death is not completely understood.
As a disturbance of the cellular redox homeostasis was reported during leukemia development and progression, we wanted to determine the potential of Trx inhibitors for ALL therapy. Additionally, we aimed to further understand the role of ROS and subsequent protein oxidation in the induction and execution of programmed cell death.
First, we demonstrated that the Trx1 inhibitor PX-12 induced cell death in three ALL cell lines. Further analysis of the events leading to PX-12-induced cell death in FADD-deficient (FD) Jurkat cells revealed an increase in ROS levels and oxidation-mediated dimer formation of peroxiredoxin 3 (PRDX3). Interestingly cell death was inhibited by the thiol-containing antioxidant N-acetylcysteine (NAC), but not by non-thiol-containing ROS scavengers. PX-12 treatment further induced cleavage of caspase-9 and -3 and activation of the pro-apoptotic BCL-2 protein BAK, leading us to the conclusion that mitochondria-dependent apoptosis was induced. Interestingly, we could demonstrate an important role for the BH3-only protein NOXA in the mediation of PX-12-induced apoptosis as knock-down of NOXA prevented cell death induction and BAK activation. Our findings give novel insights into the mechanism of PX-12-induced cell death in ALL cell lines and underscores the potential of PX-12 for the treatment of ALL.
To further understand the processes leading to cell death upon inhibition of the Trx system, we analyzed global protein oxidation in Jurkat FD cells upon treatment with the Trx reductase inhibitor Auranofin. In line with previous results, Auranofin induced intrinsic apoptosis that was dependent on BAK and accompanied by increased ROS levels. Using a BIAM Switch Assay followed by mass spectrometry, we demonstrated that Auranofin treatment induced oxidation of over 200 proteins. We identified several proteins whose oxidation upon Auranofin treatment was expected, like Trx1, Trx2 and several peroxiredoxins. Additionally, we verified oxidation of APAF1-interacting protein (APIP) and protein arginine N-methyltransferase (PRMT1) that are both implicated in the regulation of apoptosis. With this analysis we were able to demonstrate that Auranofin treatment leads to changes in global protein oxidation. Whether oxidation of the determined proteins changes their functionality and contributes to apoptosis induction remains to be elucidated.
As we identified BAK as an important player in PX-12- and Auranofin-induced cell death in the previous parts of this study, we wanted to further understand its involvement in ROS-mediated cell death. First analyses in wild-type (WT) and BAK-/- murine embryonic fibroblasts (MEFs) revealed that BAK was essential for Auranofin-induced cell death and that this cell death was caspase-independent in MEFs. Interestingly, BAK oxidation was induced upon treatment with Auranofin, but not upon stimulation with the apoptosis-inducing compound Etoposide. Expression of mutated BAK, with either one or both oxidation-sensitive cysteines mutated to oxidation-insensitive serines, revealed that mutating already one cysteine protected cells from Auranofin , but not Etoposide-induced cell death. Of note, mutation of the BAK BH3 domain rescued MEFs from both, Auranofin- and Etoposide-mediated cell death. The presence of cysteine residues also altered BAK interactions as observed by a mass spectrometric analysis of Auranofin-treated MEFs expressing either WT or cysteine-less BAK. We identified interactions of WT BAK with proteins involved in mitochondrial fission and vesicle transport upon Auranofin treatment. Of note, interaction with proteins involved in apoptosis, like BAX or BCL-XL, was not changed between WT and cysteine-less BAK. Our results demonstrate a critical role for BAK oxidation in Auranofin-induced cell death. Furthermore, we identified novel oxidation-dependent BAK interaction partners.
To conclude, this study highlights the potential of ROS-inducing treatments for ALL therapy and provides novel insights into the redox regulation of programmed cell death.